Hong Kong Biotech ETFs Surge Up to 2.9% on CGT Policy Catalyst

According to Zhi Tong Finance, today (July 6), Hong Kong biotech ETFs surged as China's National Medical Insurance Administration announced optimization of cell and gene therapy (CGT) review policies and advanced negotiations on a dual-track system combining medical insurance with commercial insurance. Industrial Capital ETF (159217.SZ) rose 2.9% to 1.172 yuan, Fidelity Industrial Capital ETF (159316.SZ) gained 2.86% to 1.152 yuan, and AMTD Industrial Capital ETF (520880.SH) climbed 2.73% to 0.452 yuan.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments